Genitourinary System Carcinoma — Trials

Genitourinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,498
Recruiting: 782
Ph III recruiting: 85
Growth YoY: +17.8%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (758)

clinicaltrialsPublishedShowing 101–150 of 762 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02844816	Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer	completed	Phase 2	172	National Cancer Institute (NCI)NIH	2	May 22, 2025	clinicaltrials
NCT02899078	Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer	completed	Phase 1 / Phase 2	31	University of California, DavisOTHER	1	May 18, 2025	clinicaltrials